Portneuf Heart and Vascular Institute using new technology
POCATELLO, Idaho (KIFI) - Portneuf Heart and Vascular (PHVI) Institute began using the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system in May 2024.
The team is honored to be among the first in the region to be chosen to use the new valve system.
TAVR is a minimally invasive alternative to open-heart valve replacement. Since performing the first groundbreaking TAVR heart surgery in 2017, the program continues to be on the cutting edge of technology.
“The Evolut FX TAVR platform is a system we know and trust,” said PMC Chief of Cardiovascular Surgery Dr. Jacob DeLaRosa. “We have used the system in our TAVR procedures over the last several years. We are eager to incorporate the Evolut FX+ TAVR system in our treatment plans for patients with symptomatic severe aortic stenosis.”
The Evlout FX+ TAVR system is used in the treatment of symptomatic severe aortic stenosis, a disease in which the aortic valve narrows and restricts blood flow from the heart. This condition requires surgical intervention.
The newest iteration of the Evolut TAVR system offers several benefits, including larger coronary access, increased space for catheter maneuverability, excellent hemodynamics and durability.
Today, roughly 270,000 people in the US are diagnosed with symptomatic severe aortic stenosis each year.
Aortic stenosis can negatively impact a person’s quality of life. If left untreated, 50% of patients with severe aortic stenosis can die from heart failure in as little as two years.
This technology is an exciting milestone that demonstrates Portneuf Heart and Vascular Institute’s commitment to improving cardiac care for heart valve disease patients.
If you or someone you know have been diagnosed with symptomatic severe aortic stenosis, talk with your doctor to determine if a TAVR procedure is right for you. Learn more at Portneuf.org/hearts.
